MedTrace Logo

Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting

NCT03516955 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 317

Last updated 2018-05-07

No results posted yet for this study

Summary

This study assessed the safety and efficacy of generic Rosuvastatin in reducing plasma low density lipoprotein (LDL) cholesterol in Lebanese adult patients (18 years or older) with dyslipidemia for both primary and secondary prevention based on their total cardiovascular risk. No visits or interventions, additional to the routine clinical practice, were requested or performed.

Conditions

  • Primary Hypercholesterolemia

Interventions

DRUG

Rosuvastatin

Superstat ® Tablets 10mg, 20mg

Sponsors & Collaborators

  • Hikma Pharmaceuticals LLC

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-08-31
Completion
2015-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03516955 on ClinicalTrials.gov